Top

Published in:

01-12-2017 | Clinical Study

Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the the Danish Neuro-Oncology Registry

Authors: Birthe Krogh Rasmussen, Steinbjørn Hansen, René J. Laursen, Michael Kosteljanetz, Henrik Schultz, Bente Mertz Nørgård, Rikke Guldberg, Kim Oren Gradel

Published in: Journal of Neuro-Oncology | Issue 3/2017

Abstract

In this national population-based study of glioma, we present epidemiologic data on incidence, demographics, survival, clinical characteristics and symptoms, and evaluate the association of specific indicators with the grade of glioma. We included 1930 patients registered in the Danish Neuro-Oncology Registry (DNOR) from 2009 to 2014. DNOR is a large-scale national population-based database including all adult glioma patients in Denmark. The age-adjusted annual incidence of histologic verified glioma was 7.3 cases pr. 100,000 person-years. High-grade gliomas were present in 85% and low-grade glioma in 15%. The overall male:female ratio was 3:2 and the mean age at onset was 60 years. Data for WHO grade I, II, III and IV glioma showed several important differences regarding age and sex distribution and symptomatology at presentation. The mean age increased with the grade of glioma and males predominated in all grades. Focal deficits were the most frequent presenting symptom, but among patients with glioma, grade II epileptic seizures were the most frequent symptom. Headache was a rare mono-symptomatic onset symptom. At presentation, higher age, focal deficits and cognitive change for <3 months duration, and headache <1 month were significant independent indicators of high-grade gliomas. Younger age and epileptic seizures for more than 3 months were indicative for low-grade gliomas. Survival rates for glioma grade I–IV showed decreasing survival with increasing grade. Glioma grade I–IV showed high diversity regarding several demographic and clinical characteristics emphasizing the importance of individually tailored disease treatments and support.

Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109(1):93–108CrossRefPubMed

Ostrom QT, Bauchet L, Davis FG et al (2014) The epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncology 16(7):896–913CrossRefPubMedPubMedCentral

Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64(6):479–489CrossRefPubMed

NORDCAN (2016) http://www-dep.iarc.fr/NORDCAN/English/frame.asp. Accessed 17 August 2016

The International Classification of Diseases—Oncology, version 3 (ICD-O-3) (2016) http://codes.iarc.fr/. Accessed 17 August 2016

Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 14(2):97–109CrossRef

Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131: 803–820CrossRefPubMed

Salminen E, Nuutinen JM, Huhtala S (1996) Multivariate analysis of prognostic factors in 106 patients with malignant glioma. Eur J Cancer 32A(11):1918–1923CrossRefPubMed

Stewart LA (2002) Glioma Metaanalysis Trialists (GMT) Group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018CrossRefPubMed

10.

Ostrom QT, Gittleman H, Stetson L et al (2015) Epidemiology of gliomas. Cancer Treat Res 163:1–14CrossRefPubMed

11.

Hansen S, Nielsen J, Laursen RJ et al (2016) The Danish Neuro-Oncology Registry: establishment, completeness and validity. BMC Res Notes 9:425CrossRefPubMedPubMedCentral

12.

Hansen S (2016) The Danish Neuro-Oncology Registry. Clin Epidemiol 8:629–632CrossRefPubMedPubMedCentral

13.

Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655CrossRefPubMed

14.

Statistics Denmark (2016) http://www.statistikbanken.dk/. Accessed 17 August 2016

15.

Hill AB (1965) The environment and disease: association or causation? Proc R Soc Med 58:295–300PubMedPubMedCentral

16.

Posti JP, Bori M, Kauko T et al (2015) Presenting symptoms of glioma in adults. Acta Neurol Scand 131:88–93CrossRefPubMed

17.

Baldi I, Gruber A, Alioum A et al (2011) Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period 2000–2007. Neuro-Oncology 13(12):1370–1378CrossRefPubMedPubMedCentral

18.

Ho VKY, Reijneveld JC, Roelien HE et al (2014) Changing incidence and improved survival of gliomas. Eur J Cancer 50:2309–2318CrossRefPubMed

19.

Christensen HC, Kosteljanetz M, Johansen C (2003) Incidence of gliomas and meningiomas in Denmark, 1943 to 1997. Neurosurgery 52:1327–1334CrossRefPubMed

20.

Deltour I, Auvinen A, Feychting M et al (2012) Mobile phone use and incidence of glioma in the Nordic countries 1979–2008: consistency check. Epidemiology 23(2):301–307CrossRefPubMed

21.

Deltour I, Johansen C, Auvinen A et al (2009) Time trends in brain tumor incidence rates in Denmark, Finland, Norway and Sweden, 1974–2003. J Natl Cancer Inst 101:1721–1724CrossRefPubMed

22.

Dahlrot RH, Kristensen BW, Hjelmborg J et al (2013) A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1. Int J Clin Exp Pathol 6:31–40PubMed

23.

Dahlrot RH, Kristensen BW, Hjelmborg J et al (2013) A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1). J Neurooncol 114:309–317CrossRefPubMed

24.

Gittleman HR, Ostrom QT, Rouse CD et al (2015) Trends in Central Nervous System tumor incidence relative to other common cancer in adults, adolescents, and children in the United States, 2000 to 2010. Cancer 121:102–112CrossRefPubMed

25.

Hamilton W, Kernick D (2007) Clinical features of primary brain tumours: a case-control study using primary care records. Br J Gen Pract 57:695–699PubMedPubMedCentral

26.

Wöhrer A, Waldhör T, Heinzl M et al (2009) The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 95:401–411CrossRefPubMed

27.

Probst HB, Hussain ZB, Andersen O (2012) Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians—a national Danish project. Health Policy 105:65–70CrossRefPubMed

28.

Schmidt-Hansen M, Berendse S, Hamilton W (2015) Symptomatic diagnosis of cancer of the brain and central nervous system in primary care: a systematic review. Fam Pract 32(6):618–623CrossRefPubMed

29.

Lipton RB, Bigal ME, Diamond M et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343–349CrossRefPubMed

30.

Rasmussen BK (1995) Epidemiology of headache. Cephalalgia 15:45–68CrossRefPubMed

31.

Laursen EL, Rasmussen BK (2012) A brain cancer pathway in clinical practice. Danish Med J 59(5):A4437

32.

Valentinis L, Tuniz F, Valent et al (2010) Headache attributed to intracranial tumors: a prospective cohort study. Cephalalgia 30(4):389–398PubMed

33.

Schankin CJ, Ferrari U, Reinish VM et al (2007) Characteristics of brain tumor-associated headache. Cephalalgia 27:904–911CrossRefPubMed

34.

Kahn K, Finkel A (2014) It IS a tumor—current review of headache and brain tumor. Curr Pain Headache Rep 18:421CrossRefPubMed

35.

Goffaux P (2010) Brain tumor headaches: from bedside to bench. Neurosurgery 67:459–466CrossRefPubMed

36.

Kirby S, Purdy A (2014) Headaches and brain tumors. Neurol Clin 32:423–432CrossRefPubMed

37.

De Luca GC, Bartleson JD (2010) When and how to investigate the patient with headache. Semin Neurol 30(2):131–144CrossRefPubMed

38.

Schwartzbaum J, Jonsson F, Ahlbom A et al (2005) Prior hospitalization for epilepsy, diabetes, and stroke and subsequent glioma and meningioma risk. Cancer Epidemiol Biomarkers Prev 14:643–650CrossRefPubMed

39.

Tucha O, Smely C, Preier M et al (2000) Cognitive deficits before treatment among patients with brain tumors. Neurosurgery 47:324–334CrossRefPubMed

Title: Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the the Danish Neuro-Oncology Registry
Authors: Birthe Krogh Rasmussen
Steinbjørn Hansen
René J. Laursen
Michael Kosteljanetz
Henrik Schultz
Bente Mertz Nørgård
Rikke Guldberg
Kim Oren Gradel
Publication date: 01-12-2017
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2607-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the the Danish Neuro-Oncology Registry

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Association between hospital volume and receipt of treatment and survival in patients with glioblastoma

Skin toxicities associated with tumor treating fields: case based review

Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status

SHP2 regulates proliferation and tumorigenicity of glioma stem cells

Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy?

Metastatic melanoma: prognostic factors and survival in patients with brain metastases